Suppression of inhibitor of differentiation 2, a target of mutant p53, is required for gain-of-function mutations.

Overexpression of mutant p53 is a common theme in human tumors, suggesting a tumor-promoting gain-of-function for mutant p53. To elucidate whether and how mutant p53 acquires its gain-of-function, mutant p53 is inducibly knocked down in the SW480 colon cancer cell line, which contains mutant p53(R273H/P309S), and the MIA PaCa-2 pancreatic cancer cell line, which contains mutant p53(R248W). We found that knockdown of mutant p53 markedly inhibits cell proliferation. In addition, knockdown of mutant p53 sensitizes tumor cells to growth suppression by various chemotherapeutic drugs. To determine whether a gene involved in cell growth and survival is regulated by mutant p53, gene expression profiling analysis was performed and showed that the expression level of Id2, a member of the inhibitor of differentiation (Id) family, was markedly increased upon knockdown of mutant p53. To confirm this, Northern blot analysis was performed and showed that the expression level of Id2 was regulated by various mutant p53s in multiple cell lines. In addition, we found that the Id2 promoter is responsive to mutant but not wild-type p53, and mutant p53 binds to the Id2 promoter. Consistent with these observations, expression of endogenous Id2 was found to be inhibited by exogenous mutant p53 in p53-null HCT116 cells. Finally, we showed that knockdown of Id2 can restore the proliferative potential of tumor cells inhibited by withdrawal of mutant p53. Together, these findings suggest that one mechanism by which mutant p53 acquires its gain-of-function is through the inhibition of Id2 expression.

[1]  A. Iavarone,et al.  Id2 Mediates Tumor Initiation, Proliferation, and Angiogenesis in Rb Mutant Mice , 2005, Molecular and Cellular Biology.

[2]  P. Chène,et al.  The gain of function of the p53 mutant Asp281Gly is dependent on its ability to form tetramers. , 2002, Cancer letters.

[3]  Y. Itahana,et al.  Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells. , 2003, Cancer research.

[4]  T. Jacks,et al.  Mutant p53 Gain of Function in Two Mouse Models of Li-Fraumeni Syndrome , 2004, Cell.

[5]  K. Kinzler,et al.  Disruption of p53 in human cancer cells alters the responses to therapeutic agents. , 1999, The Journal of clinical investigation.

[6]  M. Cummings,et al.  Expression profiling correlates with treatment response in women with advanced serous epithelial ovarian cancer , 2006, International journal of cancer.

[7]  Giulia Piaggio,et al.  Gain of function of mutant p53: the mutant p53/NF-Y protein complex reveals an aberrant transcriptional mechanism of cell cycle regulation. , 2006, Cancer cell.

[8]  Wensheng Yan,et al.  Targeted repression of bone morphogenetic protein 7, a novel target of the p53 family, triggers proliferative defect in p53-deficient breast cancer cells. , 2007, Cancer research.

[9]  C. Prives,et al.  Mutant p53 gain of function: the NF-Y connection. , 2006, Cancer Cell.

[10]  Xinbin Chen,et al.  The Activation Domains, the Proline-rich Domain, and the C-terminal Basic Domain in p53 Are Necessary for Acetylation of Histones on the Proximal p21 Promoter and Interaction with p300/CREB-binding Protein* , 2003, The Journal of Biological Chemistry.

[11]  A. Iavarone,et al.  Id2 Drives Differentiation and Suppresses Tumor Formation in the Intestinal Epithelium , 2004, Cancer Research.

[12]  V. Rotter,et al.  Mutant p53 enhances nuclear factor kappaB activation by tumor necrosis factor alpha in cancer cells. , 2007, Cancer research.

[13]  J. Cleveland,et al.  Activation of c-myc Gene Expression by Tumor-Derived p53 Mutants Requires a Discrete C-Terminal Domain , 1998, Molecular and Cellular Biology.

[14]  G. Zambetti,et al.  The p53 mutation “gradient effect” and its clinical implications , 2007, Journal of cellular physiology.

[15]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[16]  A. Iavarone,et al.  The protein ENH is a cytoplasmic sequestration factor for Id2 in normal and tumor cells from the nervous system. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[17]  F. Kittrell,et al.  Ataxia telangiectasia-mutated and p53 are potential mediators of chloroquine-induced resistance to mammary carcinogenesis. , 2007, Cancer research.

[18]  N. Sarvetnick,et al.  BMP4 Regulates Pancreatic Progenitor Cell Expansion through Id2* , 2006, Journal of Biological Chemistry.

[19]  M. Scian,et al.  Tumor-Derived p53 Mutants Induce NF-κB2 Gene Expression , 2005, Molecular and Cellular Biology.

[20]  W. Deppert,et al.  Mutant p53R270H gain of function phenotype in a mouse model for oncogene‐induced mammary carcinogenesis , 2007, International journal of cancer.

[21]  L. Strong,et al.  Gain of Function of a p53 Hot Spot Mutation in a Mouse Model of Li-Fraumeni Syndrome , 2004, Cell.

[22]  R. Alani,et al.  Id proteins in cell growth and tumorigenesis. , 2003, Cancer cell.

[23]  M. Christmann,et al.  Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks. , 2007, Cancer research.

[24]  X. Chen,et al.  p53, through p21 (WAF1/CIP1), induces cyclin D1 synthesis. , 1995, Cancer research.

[25]  J. Manola,et al.  TP53 mutations and survival in squamous-cell carcinoma of the head and neck. , 2007, The New England journal of medicine.

[26]  A. Iavarone,et al.  E Proteins and Id2 Converge on p57Kip2 To Regulate Cell Cycle in Neural Cells , 2006, Molecular and Cellular Biology.

[27]  Xinbin Chen,et al.  Identification of a Novel p53 Functional Domain That Is Necessary for Mediating Apoptosis* , 1998, The Journal of Biological Chemistry.

[28]  G. Blandino,et al.  Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression , 2006, Oncogene.

[29]  G. Landberg,et al.  High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells , 2005, International journal of cancer.

[30]  Xinbin Chen,et al.  p21B, a variant of p21Waf1/Cip1, is induced by the p53 family , 2002, Oncogene.

[31]  Jean-Philippe Coppé,et al.  Id proteins in epithelial cells. , 2003, Experimental cell research.

[32]  Justis P. Ehlers,et al.  Functional gene expression analysis uncovers phenotypic switch in aggressive uveal melanomas. , 2006, Cancer research.